{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T10:00:18Z","timestamp":1777197618411,"version":"3.51.4"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":2335,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Hypogonadism is defined as decreased testosterone levels in men. Hypogonadism can be accompanied by erectile, orgasmic, and ejaculatory dysfunction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>To evaluate whether treatment with testosterone solution 2% (testosterone) could improve ejaculatory function in a cohort of hypogonadal men.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Sexually active, hypogonadal men at least 18 years old (total testosterone &amp;lt; 300 ng\/dL) were randomized to receive testosterone or placebo for 12 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Effects of testosterone on primary outcomes were evaluated using the International Index of Erectile Function (IIEF) and the Men's Sexual Health Questionnaire, Ejaculatory Dysfunction, Short Form (MSHQ-EjD-SF) questionnaires. Treatment differences were calculated using analysis of covariance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 715 men (mean age = 55 years) were randomized to placebo (n = 357) or testosterone (n = 358). Most sexually active men who reported IIEF scores had some degree of erectile dysfunction (IIEF erectile function score &amp;lt; 26). Although ejaculatory function score (MSHQ-EjD-SF) improved in the testosterone group compared with placebo (P &amp;lt; .001), improvement on the \u201cbother\u201d item did not reach statistical significance. Treatment-related adverse events in the testosterone group affecting at least 1% of patients were increased hematocrit, upper respiratory tract infection, arthralgia, burning sensation, fatigue, increased prostate-specific antigen, erythema, and cough. Few patients in either treatment group developed at least one adverse event leading to discontinuation (testosterone = 1.98% vs placebo = 3.09%; P = .475).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Hypogonadal men receiving testosterone solution 2% therapy experience significantly greater improvement in ejaculatory function, compared with placebo, as assessed by the MSHQ-EjD-SF. However, improvement in \u201cbother\u201d was not statistically different between the two groups. Testosterone therapy was generally well tolerated.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1016\/j.jsxm.2016.05.012","type":"journal-article","created":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T03:15:20Z","timestamp":1468811720000},"page":"1220-1226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact of Testosterone Solution 2% on Ejaculatory Dysfunction in Hypogonadal Men"],"prefix":"10.1093","volume":"13","author":[{"given":"Mario","family":"Maggi","sequence":"first","affiliation":[{"name":"Department of Clinical Physiopathology \u00a0 , Florence, , Italy"},{"name":"University of Florence \u00a0 , Florence, , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darell","family":"Heiselman","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Knorr","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smriti","family":"Iyengar","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darius A.","family":"Paduch","sequence":"additional","affiliation":[{"name":"Department of Urology \u00a0 , New York, NY , USA"},{"name":"Weill Cornell Medical College \u00a0 , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig F.","family":"Donatucci","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,8,1]]},"reference":[{"key":"2024032602350707500_bib1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4158\/EP.8.6.439","article-title":"American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients\u20142002 update","volume":"8","author":"Petak","year":"2002","journal-title":"Endocr Pract"},{"key":"2024032602350707500_bib2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.eururo.2005.02.015","article-title":"Correlations between hormones, physical, and affective parameters in aging urologic outpatients","volume":"47","author":"Beutel","year":"2005","journal-title":"Eur Urol"},{"key":"2024032602350707500_bib3","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/ijcp.12418","article-title":"Experiences and treatment patterns of hypogonadal men in a U.S. health system","volume":"68","author":"Shortridge","year":"2014","journal-title":"Int J Clin Pract"},{"key":"2024032602350707500_bib4","first-page":"122","article-title":"Relationship between testosterone and erectile dysfunction","volume":"2","author":"Rajfer","year":"2000","journal-title":"Rev Urol"},{"key":"2024032602350707500_bib5","first-page":"207","article-title":"The role of serum testosterone testing: routine hormone analysis is an essential part of the initial screening of men with erectile dysfunction","volume":"6","author":"Gore","year":"2004","journal-title":"Rev Urol"},{"key":"2024032602350707500_bib6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1532-5415.2001.49088.x","article-title":"Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study","volume":"49","author":"Blanker","year":"2001","journal-title":"J Am Geriatr Soc"},{"key":"2024032602350707500_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/sj.ijir.3901250","article-title":"Sexual problems among women and men aged 40\u201380 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors","volume":"17","author":"Laumann","year":"2005","journal-title":"Int J Impot Res"},{"key":"2024032602350707500_bib8","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1743-6109.2008.00803.x","article-title":"Different testosterone levels are associated with ejaculatory dysfunction","volume":"5","author":"Corona","year":"2008","journal-title":"J Sex Med"},{"key":"2024032602350707500_bib9","volume-title":"Axiron package insert","author":"Eli Lilly and Company"},{"key":"2024032602350707500_bib10","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1365-2265.2011.04152.x","article-title":"Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men","volume":"75","author":"Wang","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024032602350707500_bib11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.juro.2015.10.083","article-title":"Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study","volume":"195","author":"Brock","year":"2016","journal-title":"J Urol"},{"key":"2024032602350707500_bib12","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The International Index of Erectile Function (IIEF): a multidimensional scale for the assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"key":"2024032602350707500_bib13","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.urology.2007.02.036","article-title":"Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction","volume":"69","author":"Rosen","year":"2007","journal-title":"Urology"},{"key":"2024032602350707500_bib14","volume-title":"Summary minutes of the joint meeting of the bone, reproductive and urologic drugs advisory committee and the drug safety and risk management advisory committee meeting","author":"Food and Drug Administration, Center for Drug Evaluation and Research","year":"2014"},{"key":"2024032602350707500_bib15","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1210\/jc.2014-4434","article-title":"Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial","volume":"100","author":"Paduch","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032602350707500_bib16","article-title":"Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men: a randomized controlled trial","volume-title":"Poster presented at: 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America","author":"Paduch","year":"2014"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609516302569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609516302569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/13\/8\/1220\/48194619\/jsm_13_8_1220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/13\/8\/1220\/48194619\/jsm_13_8_1220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T02:53:09Z","timestamp":1711421589000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/13\/8\/1220\/6940471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,1]]},"references-count":16,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,1]]},"published-print":{"date-parts":[[2016,8,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2016.05.012","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,8]]},"published":{"date-parts":[[2016,8,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Testosterone Solution 2% on Ejaculatory Dysfunction in Hypogonadal Men","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2016.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016, International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}